🌍·May 31Industry
EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors – Poster Presentation, ASCO 2026
Publisher
E
Eikon Therapeutics
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Eikon Therapeutics
- Region
- Global
- Scope
- Industry
- Published
- May 31, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on eikontx.com
Leave the platform to read the original full article on the publisher site.
Source: Eikon Therapeutics
Scope: Industry
Related coverage
More related coverage
Natco Pharma/10h ago
natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26
Natco Pharma/10h ago
natco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26
Natco Pharma/10h ago
natco receives tentative approval for olaparib tablets from the united states food and drug administration u s fda
Natco Pharma/10h ago